Gensight biologics announces approval of all resolutions supported by the board of directors at the combined general meeting of may 13, 2025

Paris--(business wire)--regulatory news: the combined general meeting of shareholders of gensight biologics (euronext: sight, isin: fr0013183985, pea-pme eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, took place on may 13, 2025, at 2:00 pm cest at the company's headquarters, 74 rue du faubourg saint-antoine, 75012 paris, france. the general meeting was chaired by laur.
GM Ratings Summary
GM Quant Ranking